Anthera Pharmaceuticals Inc. (ANTH) Trading Up 4.8%
Anthera Pharmaceuticals Inc. (NASDAQ:ANTH)’s share price was up 4.8% during trading on Thursday . The company traded as high as $3.40 and last traded at $3.29, with a volume of 388,560 shares traded. The stock had previously closed at $3.14.
A number of equities analysts have recently commented on ANTH shares. Zacks Investment Research downgraded shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 19th. Jefferies Group reaffirmed a “buy” rating on shares of Anthera Pharmaceuticals in a report on Thursday, June 9th. FBR & Co reissued a “hold” rating on shares of Anthera Pharmaceuticals in a report on Monday, June 20th. Finally, HC Wainwright started coverage on shares of Anthera Pharmaceuticals in a report on Friday, July 8th. They set a “buy” rating and a $10.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Anthera Pharmaceuticals presently has an average rating of “Buy” and an average price target of $9.58.
The company’s market capitalization is $129.93 million. The firm has a 50-day moving average price of $3.19 and a 200 day moving average price of $3.41.
Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. On average, analysts anticipate that Anthera Pharmaceuticals Inc. will post ($1.26) EPS for the current year.
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.